On September 13th, 2018 in Kiev expert discussion “Suspicion to Special Subjects: Conflict of Laws and Reasons for Escaping Liability”, organized by the Civil Oversight Council at the National Anticorruption Bureau of Ukraine together with the Bar Association of Ukraine, was held.
During the discussion, Taras Bezpalyy, counsel at Legal Alliance Company, commented on the issue of position of defence with respect to service of suspicion notice to special subjects. Mr Bezpalyy also noted that the law sets an exhaustive list of subjects which have the right to inform a special category of persons of the suspicion, i.e. carry all procedural actions upon which a person will acquire the status of suspect.
During the discussion speakers, who were in particular court experts, representatives of the National Anticorruption Bureau of Ukraine, judges and practising advocates analysed such issues as peculiarities of announcing suspicion to judges, whether the Prosecutor General and head of the Specialized Anticorruption Prosecutor’s Office can delegate their powers to detectives and prosecutors, how to avoid conflicts of laws and ensure fair pre-trial restriction to suspects, and also to improve the procedure for criminal prosecution of special subjects.
Contact the speaker: counsel Taras Bezpalyy, bezpalyy@l-a.com.ua
The event focused on the transformation of Ukraine's intellectual property sector on its path toward European integration.
Improving access to safe and affordable medicines for the Ukrainian population is one of the Government of Ukraine's top priorities. SAFEMed Activity (2017-2025) has supported this effort by appIying health system strengthening best practices.
The Ministry of Health website has posted a notice about the release of a revised draft order of the Ministry of Health ‘On Approval of Amendments to Certain Re
On 25 September, a webinar was held on the topic: ‘180 days of new drug price regulation. Results, prospects and practical advice.’ The event was organized by LA Law Firm in partnership with Proxima Research International.
